Portfolio holdings

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Woodford Patient Capital Trust plc

Home > Funds > Woodford Patient Capital Trust plc > Portfolio Holdings

We recognise that openness and transparency are key in building client understanding and we ensure that our clients get unprecedented levels of clear and relevant information about their investments, including unparalleled access to our Investment team and transparency into our portfolio construction.

To keep our investors informed, we are committed to providing full disclosure of the Woodford Patient Capital Trust’s holdings on a monthly basis.

Please find the portfolio holdings as at 31 December 2017 below.

The details set out are for information purposes only. Care is taken in ensuring this is accurate as at the stated date. However, this is not guaranteed and the portfolio may change at any time. This does not constitute investment advice or any recommendation with regard to the listed stocks.

Register now to receive Portfolio disclosure alerts by email.

Woodford Patient Capital Trust plc As at 31 December 2017
  Name Industry % (weight)
1 Oxford Nanopore (unquoted) Health Care 9.43
2 Prothena Health Care 9.22
3 Benevolent AI (unquoted) Technology 7.13
4 Purplebricks Financials 7.05
5 Immunocore A (unquoted) Health Care 6.85
6 Proton Partners International (unquoted) Health Care 4.50
7 Mereo Biopharma Health Care 4.35
8 Autolus (unquoted) Health Care 4.27
9 Atom Bank (unquoted) Financials 4.24
10 Theravance Biopharma Health Care 3.84
11 Oxford Sciences Innovation (unquoted) Financials 3.60
12 Gigaclear (unquoted) Telecommunications 2.94
13 Kymab B Pref (unquoted) Health Care 2.83
14 Cell Medica (unquoted) Health Care 2.65
15 Ultrahaptics Pref (unquoted) Technology 2.03
16 Ombu (unquoted) Financials 2.01
17 Precision Biopsy (unquoted) Health Care 1.93
18 Idex Technology 1.80
19 Arix Bioscience  Financials 1.64
20 Mission Therapeutics (unquoted) Health Care 1.63
21 Malin Financials 1.58
22 A J Bell (unquoted) Financials 1.55
23 Thin Film Electronics Industrials 1.46
24 Autolus Pref C  (unquoted) Health Care 1.45
25 Evofem D (unquoted) Health Care 1.32
26 Inivata (unquoted) Health Care 1.31
27 Cequr (unquoted) Health Care 1.26
28 Federated Wireless (unquoted) Technology 1.22
29 4D Pharma Health Care 1.21
30 Xeros Industrials 1.21
31 ReNeuron Health Care 1.18
32 Sabina Estates Pref C Financials 1.16
33 SciFluor Life Sciences (unquoted) Health Care 1.09
34 AMO Pharma (unquoted) Health Care 1.06
35 Netscientific Health Care 1.05
36 Seedrs (unquoted) Financials 1.00
37 Industrial Heat A1 Pref (unquoted) Industrials 0.91
38 Drayson Technologies (unquoted) Technology 0.80
39 Benchmark Health Care 0.74
40 Mercia Technologies Financials 0.70
41 Nexeon (unquoted) Industrials 0.69
42 ABLS Capital (unquoted) Health Care 0.64
43 Kind Consumer C (unquoted) Consumer Goods 0.59
44 Mafic (unquoted) Industrials 0.58
45 Carrick Therapeutics (unquoted) Health Care 0.56
46 Industrial Heat A2 Pref (unquoted) Industrials 0.52
47 Ratesetter (unquoted) Financials 0.52
48 Mafic B (unquoted) Industrials 0.51
49 Accelerated Digital Ventures A (unquoted) Financials 0.44
50 Metalysis (unquoted) Industrials 0.43
51 Fibre 7 (unquoted) Industrials 0.43
52 Dementia Discovery Fund (unquoted) Health Care 0.43
53 PsiOxus (unquoted) Health Care 0.41
54 Ultrahaptics (unquoted) Technology 0.40
55 Sphere Medical Pref (unquoted) Health Care 0.39
56 Seedrs Pref (unquoted) Financials 0.35
57 Vernalis Health Care 0.35
58 Federated Wireless Pref B (unquoted) Technology 0.34
59 Genomics (unquoted) Health Care 0.33
60 RM2 International 9% convertible Industrials 0.32
61 Kind Consumer (unquoted) Consumer Goods 0.27
62 Cambridge Innovation Capital (unquoted) Financials 0.26
63 Yoyo Wallet (unquoted) Technology 0.24
64 Novabiotics (unquoted) Health Care 0.21
65 Econic (unquoted) Industrials 0.21
66 American Financial Exchange (unquoted) Financials 0.19
67 Drayson Technologies C (unquoted) Technology 0.17
68 Northwest Biotherapeutics Health Care 0.14
69 Bodle Technologies (unquoted) Technology 0.13
70 Metaboards (unquoted) Technology 0.13
71 Halosource Reg S Industrials 0.11
72 Origin (unquoted) Health Care 0.11
73 Evofem C (unquoted) Health Care 0.09
74 RM2 International Industrials 0.08
75 Origin (convertible pref) (unquoted) Health Care 0.06
76 Industrial Heat A3 (unquoted) Industrials 0.04
77 Kind Consumer B (unquoted) Consumer Goods 0.04
78 Origin (warrants) (unquoted) Health Care 0.02
79 Sphere Medical (unquoted) Health Care 0.01
80 Midatech Pharma Health Care 0.01
81 Ombu Pref (unquoted) Financials 0.01

What are the risks?

  • Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy
  • Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose investors to the risk of capital losses
  • As it can take years for young businesses to fulfil their potential, this investment requires patience
  • The value of the trust as well as any income it pays will fluctuate which may partly be the result of exchange rate changes
  • The price of shares in the trust is determined by market supply and demand, and this may be different to the net asset value of the trust
  • The trust may invest in overseas securities and be exposed to currencies other than pound sterling
  • The trust may invest in unquoted securities, which may be less liquid and more difficult to realise than publicly traded securities

Important information

We do not give investment advice so you need to decide if an investment is suitable for you. If you are unsure whether to invest, you should contact a financial adviser. The trust currently intends to conduct its affairs so that its securities can be recommended by IFAs to ordinary retail investors in accordance with the FCA’s rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The securities are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are shares in an investment trust.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address Beaufort House, 51 New North Road, Exeter, EX4 4EP.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland. The Fund’s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

© 2018 Woodford Investment Management Ltd.
All rights reserved.

By using this website you are automatically agreeing to the Woodford Investment Management Ltd privacy statement